A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or olderJean‐Luc Harousseau, Lars Möllgård, Alan K. Burnett et al.|Blood|2009Cited by 146